	US 12,472,207 B2
	Anti-inflammatory compositions and methods
Llewellyn Stephen Frank Casbolt, Mount Rankin (AU)
Assigned to RR Medsciences Pty Ltd., Gordon (AU)
Appl. No. 17/310,270
Filed by RR Medsciences Pty Ltd., Gordon (AU)
PCT Filed Jan. 28, 2020, PCT No. PCT/AU2020/050053 § 371(c)(1), (2) Date Jul. 27, 2021, PCT Pub. No. WO2020/154762, PCT Pub. Date Aug. 6, 2020.
Claims priority of application No. 2019900251 (AU), filed on Jan. 28, 2019.
Prior Publication US 2022/0168339 A1, Jun. 2, 2022
Int. Cl. A61K 33/34 (2006.01); A61K 8/19 (2006.01); A61K 9/00 (2006.01); A61K 47/18 (2017.01); A61Q 17/04 (2006.01)

CPC A61K 33/34 (2013.01) [A61K 8/19 (2013.01); A61K 9/0014 (2013.01); A61K 47/183 (2013.01); A61Q 17/04 (2013.01); A61K 2800/58 (2013.01)]

20 Claims

1. A method of reducing an inflammatory response in a subject, the method comprising administering to the subject a composition comprising a copper ion complex or a mixture of copper ion complexes obtained by a process comprising:

(a) contacting copper having a specific surface area of from about 0.1 m²/kg to about 2 m²/kg, or in the form of particles having a bulk density of between about 0.2 and about 8.0 g/cm³, with a chelating agent in solid form; and

(b) while the copper is in contact with the chelating agent, contacting the copper and chelating agent with an oxidising agent, to form the copper ion complex or mixture of copper ion complexes;

wherein the composition further comprises hyaluronic acid, a salt of hyaluronic acid, or a mixture thereof;

to thereby reduce the inflammatory response in the subject.